LUNG ALERT: Doubling the dose of inhaled corticosteroid for asthma exacerbations does not decrease subsequent use of systematic steroids

Soth, M.
April 2004
Thorax;Apr2004, Vol. 59 Issue 4, p346
Academic Journal
This double blinded trial with concealed randomisation compared doubling the dose of inhaled corticosteroid for 14 days with continuing the same dose when asthma symptoms or peak flow worsened in patients monitoring themselves daily at home. All patients were using an inhaled corticosteroid through a study inhaler or placebo. During the 1 year study period 53% of patients started their study inhaler due to worsening asthma and 11 % in the treatment group versus 12% in the placebo group started oral prednisolone because of fall in peak flow of >40%, subjectively worsening asthma or an advice of their general practitioner. There was no difference in oral steroid use when analysed among those who used the study inhaler.


Related Articles

  • Warn patients over test-firing inhalers.  // Pulse;10/20/2003, Vol. 63 Issue 42, p11 

    Reports on the recommendation for general practitioners to warn asthma patients to test-fire their inhalers before using them in Great Britain.

  • Systemic Availability of Inhaled Budesonide and Fluticasone Propionate: Healthy versus Asthmatic Lungs. Harrison, T.W. // BioDrugs;2001, Vol. 15 Issue 6, p405 

    Inhaled corticosteroids are now recommended for the majority of patients with asthma. Although their therapeutic ratio is superior to that of oral corticosteroids, their long term use is associated with several potentially important adverse effects. A number of studies have compared the efficacy...

  • Ciclesonide. Reynolds, Neil A.; Scott, Lesley J. // Drugs;2004, Vol. 64 Issue 5, p511 

    â–´ Ciclesonide is an inhaled corticosteroid (delivered via a hydrofluoroalkane metered-dose inhaler) that is converted to an active metabolite, desisobutyryl-ciclesonide, in the lung, thereby minimising effects on endogenous cortisol. â–´ In two 12-week, randomised studies in patients...

  • Inhaled Mometasone Furoate: A Review of its Use in Persistent Asthma in Adults and Adolescents. McCormack, Paul L.; Plosker, Greg L. // Drugs;2006, Vol. 66 Issue 8, p1151 

    Inhaled mometasone furoate (Asmanex) is a synthetic corticosteroid indicated for the first-line maintenance prophylactic therapy of persistent asthma in adults and adolescents. It is formulated for delivery via a breath-actuated dry powder inhaler (DPI) [Twisthaler].Inhaled mometasone furoate...

  • A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. Huber, Adam M.; King, Jim; McLaine, Peter; Klassen, Terry; Pothos, Mary // BMC Medicine;2004, Vol. 2, p7 

    Background: Henoch Schönlein Purpura (HSP) is the most common systemic vasculitis of childhood. There is considerable controversy over whether children with HSP should be treated with corticosteroids. The goal of this study was to investigate whether early corticosteroid administration could...

  • Treating Pemphigus Vulgaris with Prednisone and Mycophenolate Mofetil: A Multicenter, Randomized, Placebo-Controlled Trial. Beissert, Stefan; Mimouni, Daniel; Kanwar, Amrinder J.; Solomons, Neil; Kalia, Veena; Anhalt, Grant J. // Journal of Investigative Dermatology;Aug2010, Vol. 130 Issue 8, p2041 

    Non-blinded trials of pemphigus vulgaris suggest that mycophenolate mofetil (MMF) may be beneficial. In a prospective, multicenter trial, outpatients with mild or moderate pemphigus vulgaris were randomized to MMF (2 or 3 g day–1) plus oral corticosteroids or placebo plus oral...

  • Which Inhaler Combination is Best for COPD Treatment? Elliott, William T. // Clinical Oncology Alert;Apr2007 Pharmacology Watch, p1 

    The article discusses two studies which have looked at the effects of various inhaler combinations on outcomes in patients with chronic obstructive pulmonary disease (COPD). According to a study that was published in the February 22, 2007 issue of "New England Journal of Medicine," the mortality...

  • Using a single inhaler device containing an inhaled corticosteroid plus a long-acting β-adrenoceptor agonist is a practical approach in patients with moderate to severe asthma.  // Drugs & Therapy Perspectives;Mar2008, Vol. 24 Issue 3, p9 

    The combination of an inhaled corticosteroid plus a long-acting β-adrenoceptor agonist in a single inhaler device is a treatment option in patients with moderate to severe persistent asthma. Although these combination products have important benefits (e.g. improved adherence and improved...

  • Validity of performance indicators for assessing prescribing quality: the case of asthma. Pont, Lisa G.; Denig, Petra; van der Molen, Thys; van der Veen, Willem Jan; Haaijer-Ruskamp, Flora M. // European Journal of Clinical Pharmacology;Jan2004, Vol. 59 Issue 11, p833 

    Objectives. The aim of this study was to assess the concurrent validity between the identification of sub-optimal treatment based on clinical information and computer generated indicators. Indicators that are associated with sub-optimal treatment in one of the four steps of asthma management...


Read the Article


Sign out of this library

Other Topics